A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health

Acta Psychiatrica Scandinavica

Volumn 121, Issue 6, 2010, Pages 471-479

  Warburton, W ^a   Hertzman, C ^a   Oberlander, T F ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Late prenatal selective serotonin reuptake inhibitor antidepressant exposure; Neonatal health; Prenatal depression

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; CHILD HEALTH; CONFOUNDING VARIABLE; CONVULSION; DISEASE SEVERITY; DRUG EXPOSURE; ENVIRONMENTAL EXPOSURE; FEEDING DISORDER; HOSPITALIZATION; HUMAN; JAUNDICE; LENGTH OF STAY; MATERNAL WELFARE; OUTCOME ASSESSMENT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REGISTER; RESPIRATORY DISTRESS; RISK ASSESSMENT; THIRD TRIMESTER PREGNANCY; TREATMENT WITHDRAWAL;

ADULT; ANTIDEPRESSIVE AGENTS; BRITISH COLUMBIA; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT, NEWBORN; PERINATAL CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, THIRD; PRENATAL EXPOSURE DELAYED EFFECTS; REGISTRIES; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; WITHHOLDING TREATMENT;

EID: 77951923879     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2009.01490.x     Document Type: Article

References (43)

1. Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005 293 : 2372 2383. (Pubitemid 40676760)
2. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996 335 : 1010 1015. (Pubitemid 26338730)
3. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006 160 : 173 176. (Pubitemid 43213863)
4. Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006 354 : 579 587. (Pubitemid 43209105)
5. Koren G, Matsui D, Einarson A, Knoppert D, Steiner M. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? CMAJ 2005 172 : 1457 1459. (Pubitemid 40799750)
6. Food and Drug Administration. Evaluation of Human Pregnancy Outcome Data. http://www fda gov/cder/guidance/index htm 1999Available from: URL: http://www.fda.gov/cder/guidance/index.htm
7. Health Canada. Health Canada advises of potential adverse effects of SSRIs and other anti-depressants on newborns. http://www.hc-sc.gc.ca/ahc-asc/ media/advisories-avis/-2004/2004-44-eng.php. 4 A.D. Aug 9. Report No.: http://www.hc-sc.gc.ca/english/protection/warnings/2004/2004-44.htm.
8. US Food and Drug Administration. FDA Medwatch Drug Alert on Effexor (venlafaxine HCI) and Effexor XR (venlafaxine HCI) http://www.fda.gov/medwatch/ safety/2004/safety04.htm#effexor. 2004 Jun 3. Report No.: http://www.fda.gov/ medwatch/safety/2004/safety04.htm#effexor.
9. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004 65 : 230 237.
10. Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit 2004 26 : 685 687. (Pubitemid 39579152)
11. Oberlander TF, Eckstein GR, Fitzgerald C et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002 51 : 443 453. (Pubitemid 34267314)
12. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004 113 : 368 375.
13. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006 63 : 898 906. (Pubitemid 44188483)
14. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002 159 : 2055 2061.
15. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: Population-based study. Br J Psychiatry 2008 192 : 338 343. (Pubitemid 351692377)
16. Teleplan Record Specifications Version 4.0. http://www.hlth.gov.bc.ca/ msp/infoprac/diagcodes/index.html. http://www hlth gov bc ca/msp/infoprac/ teleplanspecs/ch1 pdf, page 27 2004Available from: URL: http://www.hlth.gov.bc. ca/msp/infoprac/diagcodes/index.html.
17. Chamberlayne R, Green B, Barer ML, Hertzman C, Lawrence WJ, Sheps SB. Creating a population-based linked health database: A new resource for health services research. Can J Public Health 1998 89 : 270 273. (Pubitemid 28454432)
18. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 1998 12 : 305 313. (Pubitemid 28548587)
19. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008 83 : 68 76. (Pubitemid 351317794)
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983 70 : 41 55.
21. Foster ME. Propensity score matching an illustrative analysis of dose response. Medial Care 2003 41 : 1183 1192.
22. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007 164 : 1206 1213. (Pubitemid 47292409)
23. Nulman I, Rovet J, Stewart DE et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997 336 : 258 262. (Pubitemid 27044627)
24. Koren G, Nulman I, Addis A. Outcome of children exposed in utero to fluoxetine: A critical review. Depress Anxiety 1998 8 (Suppl 1 27 31. (Pubitemid 28524843)
25. Kulin NA, Pastuszak A, Koren G. Are the new SSRIs safe for pregnant women? Can Fam Physician 1998 44 : 2081 2083. (Pubitemid 28517044)
26. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003 60 : 720 726. (Pubitemid 36818634)
27. Maciag D, Simpson KL, Coppinger D, Et AL. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006 31 : 47 57. (Pubitemid 43250940)
28. Weissman MM, Wickramaratne P, Nomura Y, Warner V, Pilowsky D, Verdeli H. Offspring of depressed parents: 20 years later. Am J Psychiatry 2006 163 : 1001 1008. (Pubitemid 44464486)
29. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008 13 : 65 73. (Pubitemid 350275180)
30. Kim J, Riggs KW, Misri S et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol 2006 61 : 155 163. (Pubitemid 43382609)
31. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998 51 : 215 235.
32. Bogetto F, Bellino S, Revello RB, Patria L. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: A clinical investigation. CNS Drugs 2002 16 : 273 283. (Pubitemid 34492934)
33. Michelson D, Amsterdam J, Apter J et al. Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology 2000 25 : 169 177. (Pubitemid 29525389)
34. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005 352 : 1112 1120.
35. Isbister GK, Dawson A, Whyte IM, Prior FH, Clancy C, Smith AJ. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child 2001 85 : F147 F148.
36. Lejoyeux M, Ades J. Antidepressant discontinuation: A review of the literature. J Clin Psychiatry 1997 58 (Suppl 7 11 15. (Pubitemid 27305034)
37. Henry ME, Kaufman MJ, Hennen J et al. Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment. Biol Psychiatry 2003 53 : 100 105. (Pubitemid 36050941)
38. Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005 115 : 411 425. (Pubitemid 43193826)
39. Ferreira E, Carceller AM, Agogue C et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007 119 : 52 59. (Pubitemid 46397842)
40. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004 158 : 312 316. (Pubitemid 38451555)
41. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: A pharmacokinetic perspective. CNS Drugs 2001 15 : 469 494. (Pubitemid 32601905)
42. Reis M, Åberg-Wistedt A, Ågren H, Åkerblad AC, Bengtsson F. Compliance with SSRI medication during 6 months of treatment for major depression: An evaluation by determination of repeated serum drug concentrations. J Affect Disord 2004 82 : 443 446. (Pubitemid 39536177)
43. Wisner KL, Zarin DA, Holmboe ES et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000 157 : 1933 1940.